Guidant's Duet Stent Paces 34% Growth In Vascular Intervention Sales
This article was originally published in The Gray Sheet
Guidant's Multi-Link Duet coronary stent garnered nearly half of the U.S. stent market in the third quarter of 1999, the company reported Oct. 14, pacing a 34% growth in the company's vascular intervention business to $290.1 mil.
You may also be interested in...
Owens & Minor launched a search to replace its retiring CEO; Laurimed named its new CEO; Xagenic hired a VP of product development; and Intersect ENT appointed a chief commercial officer.
Guidant has begun shipping its Ancure endovascular graft for treatment of abdominal aortic aneurysm, and Medtronic is expected to launch its AneuRx AAA device shortly once the company's surgeon training program is finalized. FDA simultaneously approved the two devices on Sept. 28.
Discussions between Abbott Labs and FDA over a proposed consent decree that could halt production of certain diagnostic products likely relate to quality system regulations (QSR) violations detected over a year ago at the firm's Abbott Park, Illinois facility.